At first glance, based on the myofibroblast theory, systemically targeting the TGF-β pathway pharmacologically (e.g., via inhibition of TGF-β ligand, TGF-β receptor kinase inhibitors, targeting upstream regulators and downstream effectors) seems to present a promising therapeutic strategy for fibromyalgia. The gene discussed is TGFB1; the disease is fibromyalgia.